This study has two aims:
Aim 1: To determine the presence of accumulation of fat within cells and the functional
consequences of this in the kidney by correlating kidney fat content with urine test results.
Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on
excess fatty acid accumulation in kidney tissue and its correlation with uric acid stone
formation in subjects with uric acid stones.
Pioglitazone is already U.S. Food & Drug Administration (FDA)-approved for the treatment of
type 2 diabetes, but is not approved by the FDA for treating or preventing or diagnosing
stone risk.
Phase:
N/A
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Takeda Pharmaceuticals North America, Inc.